nefazodone has been researched along with Acute Liver Injury, Drug-Induced in 30 studies
nefazodone: may be useful as an opiate adjunct
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inflammation is one condition for demonstrated variable drug response, attributed in part, to changes in function of drug transporters." | 1.39 | Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry. ( Muller, CD; Peluso, J; Saab, L; Ubeaud-Sequier, G, 2013) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| "To estimate the cumulative incidence of hepatic adverse reactions associated with antidepressants, we used cases of hepatic damage collected via spontaneous reporting and included in the Spanish Pharmacovigilance System database; for exposure, we have used data from drug sales to the Spanish National Health System." | 1.31 | Hepatotoxicity associated with the new antidepressants. ( Carvajal García-Pando, A; García del Pozo, J; Lucena, MI; Rueda de Castro, AM; Sánchez, AS; Velasco, MA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 17 (56.67) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Morgan, RE | 2 |
| Trauner, M | 1 |
| van Staden, CJ | 2 |
| Lee, PH | 1 |
| Ramachandran, B | 1 |
| Eschenberg, M | 1 |
| Afshari, CA | 2 |
| Qualls, CW | 1 |
| Lightfoot-Dunn, R | 1 |
| Hamadeh, HK | 2 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Dawson, S | 1 |
| Stahl, S | 2 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Aleo, MD | 1 |
| Luo, Y | 1 |
| Swiss, R | 1 |
| Bonin, PD | 1 |
| Potter, DM | 1 |
| Will, Y | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Norman, BH | 1 |
| Wei, H | 1 |
| Li, AP | 1 |
| Xu, Q | 1 |
| Liu, L | 1 |
| Vu, H | 1 |
| Kuhls, M | 1 |
| Aslamkhan, AG | 1 |
| Liaw, A | 1 |
| Yu, Y | 1 |
| Kaczor, A | 1 |
| Ruth, M | 1 |
| Wei, C | 1 |
| Imredy, J | 1 |
| Lebron, J | 1 |
| Pearson, K | 1 |
| Gonzalez, R | 1 |
| Mitra, K | 1 |
| Sistare, FD | 1 |
| Mattes, W | 1 |
| Davis, K | 1 |
| Fabian, E | 1 |
| Greenhaw, J | 1 |
| Herold, M | 1 |
| Looser, R | 1 |
| Mellert, W | 1 |
| Groeters, S | 1 |
| Marxfeld, H | 1 |
| Moeller, N | 1 |
| Montoya-Parra, G | 1 |
| Prokoudine, A | 1 |
| van Ravenzwaay, B | 1 |
| Strauss, V | 1 |
| Walk, T | 1 |
| Kamp, H | 1 |
| Thompson, RA | 1 |
| Isin, EM | 1 |
| Ogese, MO | 1 |
| Mettetal, JT | 1 |
| Williams, DP | 1 |
| Kim, JA | 1 |
| Han, E | 1 |
| Eun, CJ | 1 |
| Tak, YK | 1 |
| Song, JM | 1 |
| Saab, L | 1 |
| Peluso, J | 1 |
| Muller, CD | 1 |
| Ubeaud-Sequier, G | 1 |
| Ehrentraut, S | 1 |
| Rothenhäusler, HB | 1 |
| Gerbes, AL | 1 |
| Rau, HG | 1 |
| Thiel, M | 1 |
| Schirren, CA | 1 |
| Kapfhammer, HP | 1 |
| Edwards, IR | 1 |
| Spigset, O | 1 |
| Hägg, S | 1 |
| Bate, A | 1 |
| Choi, S | 1 |
| Genton, A | 1 |
| Buclin, T | 1 |
| Malani, AK | 1 |
| Ammar, H | 1 |
| Schrader, GD | 1 |
| Roberts-Thompson, IC | 1 |
| Eloubeidi, MA | 1 |
| Gaede, JT | 1 |
| Swaim, MW | 1 |
| Carvajal García-Pando, A | 1 |
| García del Pozo, J | 1 |
| Sánchez, AS | 1 |
| Velasco, MA | 1 |
| Rueda de Castro, AM | 1 |
| Lucena, MI | 1 |
| Schwetz, BA | 1 |
| Stewart, DE | 1 |
3 reviews available for nefazodone and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Eval | 2020 |
Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Chemical | 2016 |
27 other studies available for nefazodone and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2014 |
Permeabilized Cryopreserved Human Hepatocytes as an Exogenous Metabolic System in a Novel Metabolism-Dependent Cytotoxicity Assay for the Evaluation of Metabolic Activation and Detoxification of Drugs Associated with Drug-Induced Liver Injuries: Results w
Topics: Acetaminophen; Activation, Metabolic; Amiodarone; Chemical and Drug Induced Liver Injury; Cyclophosp | 2022 |
Can Galactose Be Converted to Glucose in HepG2 Cells? Improving the
Topics: Amiodarone; Benzbromarone; Chemical and Drug Induced Liver Injury; Galactose; Glucose; Hep G2 Cells; | 2019 |
Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma.
Topics: Animals; Atropine; Captopril; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Dr | 2014 |
Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity.
Topics: Apoptosis; Benzophenones; Calcium; Caspase 3; Chemical and Drug Induced Liver Injury; Chromans; Hep | 2012 |
Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2013 |
[Acute liver failure in nefazodone therapy? A case report].
Topics: Antidepressive Agents; Chemical and Drug Induced Liver Injury; Depressive Disorder; Fatal Outcome; H | 2002 |
Withdrawing drugs: nefazodone, the start of the latest saga.
Topics: Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Drug Approval; Dru | 2003 |
Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions.
Topics: Adverse Drug Reaction Reporting Systems; Bayes Theorem; Chemical and Drug Induced Liver Injury; Cycl | 2003 |
Nefazodone (Serzone) withdrawn because of hepatotoxicity.
Topics: Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Humans; Jaundice; | 2003 |
[Withdrawal of a drug from the market for safety reasons: process and communication].
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Attitude of Healt | 2004 |
Medical management of depression.
Topics: Chemical and Drug Induced Liver Injury; Depressive Disorder; Duloxetine Hydrochloride; Humans; Liver | 2006 |
Adverse effect of nefazodone: hepatitis.
Topics: Adult; Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Depression; | 1999 |
Reversible nefazodone-induced liver failure.
Topics: Antidepressive Agents, Second-Generation; Biopsy; Chemical and Drug Induced Liver Injury; Diagnosis, | 2000 |
Hepatotoxicity associated with the new antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Chemical and Drug Induced Liver Injury; Depressive Disorder; Dru | 2002 |
From the Food and Drug Administration.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Antidepress | 2002 |
Hepatic adverse reactions associated with nefazodone.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antidepressive Agents, Second-Generation; Cana | 2002 |